- Home
- SRV vs ARCT Comparison
SRV vs ARCT Comparison
Compare SRV & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SRV | ARCT |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 214.2M | 189.9M |
| IPO Year | 2007 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SRV | ARCT |
|---|---|---|
| Price | $45.10 | $8.31 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $24.11 |
| AVG Volume (30 Days) | 57.3K | ★ 412.1K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $82,031,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $37.70 | $5.85 |
| 52 Week High | $46.43 | $24.14 |
Technical Indicators
Market Signals| Indicator | SRV | ARCT |
|---|---|---|
| Relative Strength Index (RSI) | 57.83 | 52.95 |
| Support Level | $42.01 | $6.90 |
| Resistance Level | $46.24 | $8.65 |
| Average True Range (ATR) | 0.88 | 0.41 |
| MACD | 0.05 | -0.04 |
| Stochastic Oscillator | 88.68 | 19.26 |
Price Performance
Historical ComparisonAbout SRV NXG Cushing Midstream Energy Fund of Beneficial Interest
NXG Cushing Midstream Energy Fund is a non-diversified, closed-end investment company. Its investment objective is to obtain a high after-tax total return from a combination of capital appreciation and current income. The fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in a portfolio of midstream energy investments.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.